Zymeworks Shares Outstanding 2016-2022 | ZYME
Zymeworks shares outstanding from 2016 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Zymeworks Annual Shares Outstanding
(Millions of Shares) |
| 2021 |
52 |
| 2020 |
50 |
| 2019 |
38 |
| 2018 |
29 |
| 2017 |
21 |
| 2016 |
13 |
| 2015 |
27 |
Zymeworks Quarterly Shares Outstanding
(Millions of Shares) |
| 2022-06-30 |
66 |
| 2022-03-31 |
61 |
| 2021-12-31 |
52 |
| 2021-09-30 |
52 |
| 2021-06-30 |
51 |
| 2021-03-31 |
51 |
| 2020-12-31 |
50 |
| 2020-09-30 |
51 |
| 2020-06-30 |
51 |
| 2020-03-31 |
49 |
| 2019-12-31 |
38 |
| 2019-09-30 |
43 |
| 2019-06-30 |
33 |
| 2019-03-31 |
32 |
| 2018-12-31 |
29 |
| 2018-09-30 |
32 |
| 2018-06-30 |
27 |
| 2018-03-31 |
25 |
| 2017-12-31 |
21 |
| 2017-09-30 |
25 |
| 2017-06-30 |
21 |
| 2017-03-31 |
13 |
| 2016-12-31 |
13 |
| 2016-09-30 |
13 |
| 2016-06-30 |
13 |
| 2016-03-31 |
12 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.614B |
$0.027B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
